Webinar | Women’s Nutrition: Nourishing Womanhood From Pregnancy To Menopause
11 September | 12 PM ET: Register Now

Axiota Animal Health

Axiota Animal Health develops and markets products for beef and dairy producers, including MultiMin 90 and Lactipro.
2020
51-100
51-100
Fort Collins, Colorado, United States

Innovation

Industry Problem

Beef and dairy producers need to reduce disease, stress-related losses and antimicrobial use while maintaining animal performance.

R&D Focus

Rumen probiotics, injectable trace minerals and cattle health biologics.

Innovative Solution

Axiota combines Lactipro rumen-adaptation probiotics with Multimin 90 injectable trace minerals and develops additional cattle-health technologies.

Investment Funding

Last Funding Stage

Private Equity

Total Funding Amount

49.79M

Last Funding Amount

30.07M

Last Funding Date

25-03-2024

Startup Stage

Private Equity

Revenue

$1M to $10M

People

Founders

About

Axiota Animal Health operates in the biotechnology industry, focusing on the health of animals, particularly cattle. The company is known for discovering, developing, and marketing products for beef and dairy producers. Some of their notable products include MultiMin 90 and Lactipro. These products are designed to prepare cattle to thrive during transition and stress. The company also has a diverse team that brings a broad range of relevant business expertise in the areas of animal health management.

Products

Product

Lactipro: a rumen probiotic used to support cattle transition to high-energy diets. Multimin 90: an injectable source of zinc, copper, manganese and selenium.

Star Product

Lactipro, because it is Axiota’s core probiotic technology for beef and dairy production.

Demo Product or Complete Product?

Complete commercial animal-health products. Multimin 90 received expanded U.S. FDA approval in March 2025.

Awards and Recognitions

Certifications

Multimin 90 received OMRI certification for use in organic production in October 2024; expanded FDA approval was announced in March 2025.

M&A and Collabs

Collab

Resilient Biotics: agreement to co-develop respiratory-disease technology and grant Axiota exclusive global commercialization rights.

Acquisitions

Axiota was formed in 2020 by combining Multimin USA and MS Biotec under Paine Schwartz Partners.

Something missing or incorrect on this page? Help us enrich this information